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Abstract 
Antiretroviral drugs have saved and extended the lives of millions of 
individuals infected with human immunodeficiency virus type 1 (HIV-1). The 
major classes of anti-HIV-1 drugs include reverse transcriptase inhibitors, 
protease inhibitors, integrase inhibitors and entry/fusion inhibitors. While 
antiretroviral drug regimens are commonly used to treat other types of retroviral 
infections, there are instances where there is a perceived need for re-evaluation 
of the benefits of new antiretroviral therapy. One case in point is that of feline 
leukemia virus (FeLV), an infection of domesticated felines. While vaccines exist 
to prevent FeLV infection and spread, they have not eliminated FeLV infection. 
For FeLV-infected felines and their human companions, antiretroviral therapy 
would be desirable and of practical importance if good options were available.  
 The goal of this dissertation was to 1) determine the susceptibility of FeLV 
to drugs that could be amendable to clinical translation, and 2) explore the anti-
FeLV mechanism of action of these drugs. FeLV was found to be susceptible to 
two anticancer drugs (i.e., decitabine and gemcitabine) as well as two anti-HIV-1 
drugs (raltegravir and tenofovir).  FeLV, but not HIV-1, was also found to be 
susceptible to cyclopentenyl cytosine. Mechanism of action studies suggested 
that decitabine and gemcitabine did not enhance FeLV mutagenesis, which is 
contrary to previous observations of enhanced HIV-1 mutagenesis observed with 
these drugs.  Cyclopentenyl cytosine did not enhance viral mutagenesis, was 
observed to reduce dCTP levels in the Crandell-Rees feline kidney cell line, and 
  iv 
FeLV susceptibility to cyclopentenyl cytosine was enhanced by a mutation in a 
conserved region of reverse transcriptase. These studies 1) support the further 
exploration of the clinical translation of decitabine, gemcitabine and 
cyclopentenyl cytosine for the treatment of FeLV infection, and 2) suggest 
differences in the antiviral mechanisms of action of decitabine, gemcitabine and 
cyclopentenyl cytosine between FeLV and HIV-1. 
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Background 
Retroviruses are a large group of RNA viruses that are found in all 
vertebrates.  They share many common features, such as similarities in genetic 
organization and mechanism of replication – and in particular for their encoding 
for a reverse transcriptase.  These viruses are a significant source of morbidity 
and mortality in both humans and animals.  In humans, human immunodeficiency 
virus (HIV) is responsible for a pandemic that continues to be a significant cause 
of morbidity and mortality.  In animals, feline leukemia virus (FeLV) represents a 
significant source of fetal mortality and cancerous diseases in cats. Besides its 
role in feline mortality, FeLV has played an important role in advancing the 
understanding of retroviruses in general.  In fact, the characterization of FeLV as 
well as other animal retroviruses such as bovine leukemia virus and Rous 
sarcoma virus, led to the concepts and techniques that later enabled the 
discovery and characterization of human retroviruses including HIV(Levy 1993).  
Additionally, FeLV was 1) the first retrovirus in which a vaccine was developed, 
2) the first retrovirus for which a practical diagnostic test was developed, and 3) 
the first retrovirus that elicited the development of a program whose goal was to 
control its spread (Levy 1993).  Despite the significant achievements and 
understanding of FeLV biology, FeLV is still a significant source of morbidity and 
mortality in felines and the treatment options for infected cats are ineffective, 
toxic, or cost-prohibitive. Here, we discuss FeLV epidemiology, pathogenicity, 
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and current treatments as well as future drug targets that may advance the field 
of FeLV treatment. 
 
Epidemiology 
FeLV is highly transmissible through saliva and nasal secretions as well 
as through coitus and vertical transmission from queen to kitten.  Because the 
primary mode of transmission is through the oronasal route, its prevalence is 
often dictated by the extent of animal-to-animal contact.  For example, the high 
prevalence of FeLV in the stray cat population (43%) increases the risk of 
infection for indoor-outdoor cats compared to indoor only cats.  Similarly, animal-
to-animal contact contributes to the different rates of FeLV infection in single cat 
households (4-11%) compared to multicat households whose prevalence has 
been reported to be as high as 70% (Rogerson, Jarrett et al. 1975; Ettinger 2005; 
Côté 2007).   
Containment of FeLV is difficult due to transmission routes, the time 
between infection and the onset of symptoms, and the ability of latently-infected 
cats to become viremic.  In fact, exposure of cats to FeLV usually leads to one of 
three outcomes, two of which can contribute to the spread of disease (Essex, 
Cotter et al. 1973; Rogerson, Jarrett et al. 1975; Sparkes 1997; Ettinger 2005; 
Côté 2007; Levy, Crawford et al. 2008; Lutz, Addie et al. 2009).  The first 
outcome is accounted for by the 10% of exposed cats that become latently 
infected without a detectable viremia.  While these cats would not seem to be a 
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source of infection, they can become viremic, and subsequently shed virus into 
the environment.  The second outcome is represented by 40% of cats exposed to 
FeLV, and is characterized by persistent viremia and antigenemia.  These cats 
are chronically infected, and therefore represent a significant source of viral 
shedding in the environment.  The third outcome includes cats that become 
infected with FeLV, but are then able to clear the virus to the point where it is 
undetectable by standard testing methods.  Approximately 50% of cats exposed 
to FeLV fall into this last group and these cats are not considered to be a 
reservoir for viral spread (Ettinger 2005; Côté 2007). 
 
FeLV replication 
FeLV was first described by Jarrett et al in 1964 who isolated viral 
particles from lymphomas obtained from infected cats (Jarrett, Crawford et al. 
1964). Using electron microscopy, Jarrett et al described the infectious agent as 
being similar in appearance to murine leukemia virus (MuLV).  Later studies 
confirmed FeLV to be a retrovirus.  FeLV is a “simple” retrovirus, in that it 
encodes for three genes common to all retroviruses (gag, pol, and env), but lacks 
many of the additional genes found in complex retroviruses such as HIV (Chen, 
Bechtel et al. 1998; Levy, Crawford et al. 2008; Lutz, Addie et al. 2009).  As with 
other retroviruses, the gag gene encodes for structural proteins while the pol 
gene encodes for the enzymatic proteins necessary for reverse transcription of 
the FeLV genome, integration of its DNA into the host genome, and processing 
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of viral proteins.  Finally, env encodes for two envelope proteins that determine 
cellular tropism, including p15E, a transmembrane protein, and the associated 
external envelope protein, gp70 (Levy 1993).  Amino acid variation in the virus 
envelope protein has led to the division of FeLV into four different subtypes that 
defines their cell tropism:  A, B, C and T (Table 1-1) (Sarma and Log 1973; 
Jarrett, Hardy et al. 1978; Jarrett 1980).  Subtype A is considered to be the 
founder, transmitted form of FeLV with all other subtypes arising through 
mutations in FeLV A Env or by recombination events with one of the endogenous 
FeLVs (enFeLV) contained within the cat genome (Levy 1993; Kahn 2005).  The 
enFeLV has an incomplete genome, is not replication competent, and is 
theorized to have originated hundreds of thousands of years ago when a cat ate 
a mouse that was viremic with murine leukemia virus (MuLV).  Such an event 
enabled the incorporation of the MuLV genome into the genome of the cat’s germ 
line cells (Benveniste and Todaro 1973; Benveniste, Sherr et al. 1975). 
Cell-free FeLV gains entry into target cells when the envelope protein 
binds to the appropriate host receptor that is dependent on the FeLV subtype 
(Table 1-1).  Once inside of the target cell, the RNA genome is reverse 
transcribed into viral DNA by the viral protein reverse transcriptase (Coffin 1979; 
Coffin 1992; Coffin 1992; Coffin 1996).   The viral DNA is then transported into 
the nucleus where it integrates into the host genome through the enzymatic 
action of viral integrase.  The integrated viral DNA is then transcribed to produce 
RNA that serves as both viral progeny as well as mRNA for the translation of viral 
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proteins.  Translated Gag and Pol proteins are then trafficked to the cell 
membrane where the new virions bud from the cell membrane.  As the virion 
buds, proteolytic cleavage of viral proteins causes structural changes in the virion 
that are necessary for viral maturation and the formation of infectious virus 
particles (Coffin 1979; Coffin 1992; Coffin 1992; Coffin 1996). 
 
Pathobiology 
FeLV usually enters the feline host through the oronasal route either 
through mutual grooming, biting, or a shared food source (Rickard, Post et al. 
1969; Essex, Klein et al. 1971; Cattori, Tandon et al. 2009).  In the pharynx, 
FeLV infects the tonsorial B-lymphocytes and monocytes which can enter the 
draining lymph nodes (Rojko JL 1979).  The draining lymph nodes serve as a site 
of replication and as an entry point for the virus to enter the bloodstream.  Once 
in the bloodstream, the virus can gain access to and infect cells in the bone 
marrow (Levy 1993).  This represents a critical point in the infection process as it 
is thought that a persistent infection can be avoided if the immune system can 
mount an appropriate response before cells in the bone marrow are infected 
(Rojko, Hoover et al. 1979).  Once the virus becomes systemic, it infects 
epithelial cells in the intestines, stomach, trachea and salivary glands and 
becomes shed into the environment.  Persistently-infected cats can demonstrate 
symptoms of disease anywhere from weeks to years after infection.  FeLV-
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mediated disease typically falls into one of two major categories – 
cytoproliferative or immunosuppressive (Levy 1993).  
Cytoproliferative diseases associated with FeLV include leukemias, 
lymphomas, fibrosarcomas, and associated myeloproliferative disorders (Hardy, 
Hess et al. 1976; Ettinger SF 2004).  Most cytoproliferative diseases are 
attributed to insertional mutagenesis, a process where FeLV DNA integrates at a 
site in the cat’s genome that disrupts or deregulates expression of proteins 
involved in the regulation of cell cycle, cell survival or apoptosis (Levy, Lobelle-
Rich et al. 1993; Tsujimoto, Fulton et al. 1993; Levy, Starkey et al. 1997; Fujino, 
Satoh et al. 2003; Fujino, Ohno et al. 2008; Fujino, Liao et al. 2009).  In contrast, 
FeLV plays an indirect role in the formation of feline fibrosarcoma.  Specifically, 
fibrosarcoma is caused by dual infection by both FeLV and feline sarcoma virus 
(FSV).  FSV is a replication-defective virus that encodes an oncogene that drives 
cellular transformation (Snyder and Theilen 1969; Naharro, Dunn et al. 1983; 
Naharro, Tronick et al. 1983; Naharro, Robbins et al. 1984).  Therefore, FeLV 
serves as a helper virus by providing FSV with proteins that are necessary for its 
replication, which allows for expression of the FSV oncogene (Snyder and 
Theilen 1969; Naharro, Dunn et al. 1983; Naharro, Tronick et al. 1983; Naharro, 
Robbins et al. 1984).   
Besides having cytoproliferative effects, FeLV also mediates a significant 
loss of immune function.  This immune suppression is due to a progressive loss 
of T and B lymphocytes as well as neutrophils.  Immune suppression leads to 
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secondary infections such as bacterial or fungal infections that would not be a 
significant source of morbidity in an otherwise healthy cat (Perryman, Hoover et 
al. 1972; Hoover, Perryman et al. 1973; Hardy, McClelland et al. 1981; Trainin, 
Wernicke et al. 1983). Although the exact mechanism of FeLV-mediated 
immunosuppression is not clear, evidence supports three distinct mechanisms of 
action.  First, immune suppression may be a result of FeLV-mediated 
myeloproliferative disorder (Kahn 2005; Côté 2007).  This disorder leads to an 
over-proliferation of incompetent mature or immature white blood cells within the 
bone marrow that eventually overcrowd hematopoietic cells, thereby decreasing 
red blood cell production and leading to a hindrance of the immune system.  
Second, the virus may be cytopathic or induce cellular apoptosis, although most 
evidence indicates that this may be specific for FeLV subtype T.  Third, it has 
been suggested that the transmembrane envelope protein, p15E, may have 
immunosuppressive properties (Hebebrand, Olsen et al. 1979; Mathes, Olsen et 
al. 1979; Lafrado, Lewis et al. 1987; Quackenbush, Mullins et al. 1989).  For 
example, p15E has been reported to inhibit production of mitogenic lymphokines 
in T cells and has been shown to inhibit lymphocyte function without affecting 
receptor function (Mathes, Olsen et al. 1979; Lafrado, Lewis et al. 1987).  
Additionally, while p15E is not known to be cytotoxic, lymphocyte populations 
that are exposed to FeLV demonstrate a decline in size (Hebebrand, Olsen et al. 
1979; Mathes, Olsen et al. 1979; Lafrado, Lewis et al. 1987; Quackenbush, 
Mullins et al. 1989).  FeLV-mediated immunosuppression allows for secondary 
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infections such as bacterial, parasitic and other viral infections.  One example 
includes the blood borne parasitic infection, hemobartonellosis, which is seen 
with the subgroup C infections and results in anemia with a hemolytic aspect 
(Levy 1993).     
Other diseases are associated with FeLV, however the mechanisms 
remain unclear.  For example, neurological diseases and infertility are seen in 
FeLV-infected cats, though it is not clear how FeLV replication causes these 
disorders.  Also, FeLV-C is known to cause a non-regenerative aplastic anemia. 
While the mechanism is not clear, it has been suggested that the anemia may be 
due to FeLV’s use of the heme export receptor, FLVCR1, leading to a toxic 
accumulation of heme in erythroid progenitor cells and decreasing their numbers 
(Tailor, Willett et al. 1999; Quigley, Burns et al. 2000). Figure 1-1 provides a 
summary of the FeLV pathogenesis.    
 
Therapeutics:  vaccines and limitations 
Besides containment of infected cats, commercially available vaccines for 
FeLV such as Pfizer’s Leukocell® or Merial’s Purevax® are marketed and may 
significantly reduce FeLV spread and viral reservoir development.  These 
particular vaccines are derived from chemically-inactivated antigens or are of 
recombinant viral origin, respectively, and do not offer sterilizing immunity (i.e., 
these vaccines essentially prime the cat’s immune system enabling it to clear the 
virus upon exposure) (Sparkes 1997; Sparkes 2003; Hofmann-Lehmann, Tandon 
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et al. 2006).  The American Association of Feline Practitioners reserves the 
vaccination regimen for high risk populations such as indoor-outdoor cats and 
catteries rather than including it as part of the core vaccines.   
 There are several reasons why these FeLV vaccines are likely reserved 
strictly for the high-risk populations.  The link between FeLV vaccine and feline 
sarcoma is likely to play an important role in why these vaccines are not part of 
the core vaccines. Vaccine-associated sarcoma (VAS) is an aggressive 
malignant cancer, which requires aggressive surgery and often chemotherapy to 
treat (Madewell, Gieger et al. 2004; Kahn 2005; Côté 2007). The association of 
VAS is a significant reason why many owners and breeders choose not to 
vaccinate their cats against FeLV.  A second reason why the FeLV vaccine is not 
part of the core vaccines is that a "closed" population of indoor only cats, 
meaning no introduction or contract with new cats, is not susceptible to FeLV, 
making the risk of VAS greater than the risk of infection. A third factor that might 
limit the use of the FeLV vaccine is that its efficacy is still not known and is 
difficult to determine.  Further complicating the issue is that the biological 
response to FeLV exposure differs significantly among cats.  For example, 50% 
of cats clear the virus, 40% become persistently infected and another 10% 
become latently infected.  Finally, efficacy may need to be determined by using 
age-matched groups given that younger cats are more susceptible to a 
pathogenic infection compared to older individuals (Flynn, Hanlon et al. 2000; 
Kahn 2005; Côté 2007).  Analyzing the results from studies that have examined 
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efficacy is difficult because of the differences in the study design, viral strain 
used, and age at which cats were challenged with virus. 
Many owners choose not to vaccinate their cats for fear of VAS and 
because the efficacy of the vaccine is not clear.  The unvaccinated cat 
population, as well as stray cat population remains at risk for FeLV and is a 
significant source for FeLV transmission.  The prevalence of FeLV in the cat 
population is evident in veterinary care where there is a significant demand for 
the treatment of FeLV. 
 
Therapeutics:  antiviral drug targets and opportunities 
The lack of effective treatment options leads most owners to choose 
palliative care for FeLV-infected cats.  Palliative care may include medications to 
treat infections, pain management, nutritional support, or any other care with the 
goal of keeping the cats comfortable and improving their quality of life. 
Although some antivirals and immune modulators have been reported to 
improve the quality or quantity of life for FeLV infected cats, no studies have 
convincingly shown that any antivirals or immune modulators actually improve 
the quality or quantity of life for FeLV-infected felines in a clinically useful form.  
Among antivirals used to treat FeLV, azidothymidine (AZT) was the first 
antiretroviral used to treat HIV.  AZT is a nucleoside analog that gets 
incorporated into the viral DNA during reverse transcription of the RNA genome 
to double-stranded DNA.  AZT lacks the 3’-hydroxyl group necessary for DNA 
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polymerization, which results in chain termination of viral DNA synthesis.  
Although AZT is the primary antiviral used clinically to treat FeLV, there is little, if 
any, literature to support its ability to improve the course of the disease once 
infection is established.  Some studies have suggested that treatment of cats 24 
hours prior to infection up until 24 hours after infection, might delay or minimize 
infection (Tavares, Roneker et al. 1987; Nelson, Sellon et al. 1995), but there 
have been no well-designed studies to address the efficacy of AZT to prolong the 
lives of cats with established infection.  The studies that indicate that AZT might 
be efficacious demonstrated that even minor improvements in disease indicators 
were associated with drug-related toxicities.  For example, animals treated with 
doses of 30 and 60 mg/kg/day had elevated antibody titers suggesting that their 
immune system was better able to respond to infection, although all animals 
receiving these doses demonstrated drug related toxicities. (Haschek, Weigel et 
al. 1990)  Thus, the main limitation for the use of AZT is its lack of apparent 
efficacy at tolerable doses. 
Similar to antivirals, studies reporting the efficacy of immune modulators 
have small numbers, lack of appropriate controls, and/or have not been 
independently verified. One of the immune modulators with little to no support for 
efficacy is lymphocyte T-cell immune modulator (LTCI).  LTCI is a protein 
produced by a thymic stromal epithelial cell line whose manufacturers claim that 
this protein induces cytokines that activate CD8 cytotoxic T cells to attack virally-
infected cells.  It is also claimed that LTCI led to clinical improvement in FeLV-
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infected cats.  These claims are not documented in the peer-reviewed literature 
and the data supplied by the manufacturers do not argue strongly for 
improvements that are likely to improve the quality of life or length of life for FeLV 
infected animals (Gingerich 2008). 
Another immune modulator, inactivated parapoxvirus ovis, strain D1701 
(Baypamun®, Bayer, Leverkusen, Germany), is reported to non-specifically 
activate the immune system and improve or cure FeLV infected cats.  Baypamun 
is a preparation of chemically that is reported to increase neutrophil counts and 
increase the production of interferon, interleukins, and tumor necrosis factor.  
While, initial reports by Horber and Mayr reported that Baypamun cured 80 to 
100% of FeLV infected cats (Hörber D 1992; Mayr B 1992), numerous 
independent studies have failed to find a difference in the clinical response 
between cats treated with Baypamun and those treated with placebo.(Hartmann, 
Block et al. 1999)   
SPA is perhaps the only immune modulator with evidence to support its 
ability to improve FeLV infected cats.  SPA is a bacterial polypeptide purified 
from the cell walls of Staphylococcus aureus Cowan I.  Although its mechanism 
of action is not clear, it has been shown to bind preferentially to IgG in the form of 
an immune complex rather than its monomeric form.  It has been speculated that 
SPA may bind to IgG that is bound to a “blocking factor” associated with antigen-
antibody complexes and that this blocking factor may facilitate a tumor or viruses 
escape from immunological control.  Therefore, SPA removes antigen-antibody-
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blocking factor complexes, allowing the immune system to react to viral invasion.  
Others have suggested that SPA may stimulate the immune system by inducing 
antibody synthesis, expression of interferon, and by potentiating the natural killer 
activity of lymphocytes.  Although some studies have shown that SPA can 
improve the life expectancy of FeLV-infected cats, the treatment regimens 
described in these studies are too cost prohibitive and demanding to be clinically 
useful (Day, Engelman et al. 1984).  For example, the treatment regimens 
required whole body irradiation followed by treatments given twice weekly.  
Additionally, it took 14 to 45 treatments to clear the virus and even this many 
treatments did not elicit a response from all of the cats (Operario, Reynolds et al. 
2005).  Given the conflicting results on treatment efficacy in addition to the cost 
and time associated with the treatments, SPA is not a clinically feasible treatment 
option. 
 
Treatment options, drug targets, and the need for FeLV-based 
antiretrovirals 
The significant morbidity and mortality associated with FeLV combined 
with the significant knowledge of FeLV biology and availability of antiretrovirals 
developed for HIV should facilitate the identification and development of new 
treatment options for FeLV.  Perhaps one of the main problems with treating 
FeLV is that early treatment is almost a prerequisite for success. Since 
insertional mutagenesis is responsible for FeLV-mediated lymphomas and 
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leukemias, a quick decrease in viral loads would ensure fewer integration events 
thereby decreasing the likelihood of oncogenesis.  Given the success in anti-HIV 
drugs at quickly decreasing viral loads, it is reasonable to assume that some of 
these drugs could be repositioned for the treatment of FeLV.  The most likely 
classes of anti-HIV drugs that could be repositioned include the nucleoside 
reverse transcriptase inhibitors (NRTIs).  Many of the other classes of anti-HIV 
drugs are structure-based small molecule inhibitors and would therefore be 
unlikely to possess anti-FeLV activities.  Although there are a number of NRTIs 
that could be repositioned to treat FeLV, in vitro and in vivo studies indicate that 
NRTIs may not be readily repositioned to treat FeLV infections.  Biochemical 
studies have shown that reverse transcriptase (RT) from oncoretroviruses such 
as FeLV have a higher fidelity and a significantly lower susceptibility to certain 
nucleoside analogs when compared to lentiviruses.(Day, Engelman et al. 1984)  
The differences in susceptibility to nucleoside analogs between lentiviral RTs and 
oncoretroviral RTs suggest that nucleoside analogs used to treat HIV will have 
different susceptibilities for FeLV. 
 
Conclusion 
In human medicine, improvement in treatment options is driven by the 
demand of those affected by the disease.  A prominent example of this demand 
and supply is seen with conditions like cancer and HIV, where the impact on 
society fueled the funding and motivation necessary to create a rapid expansion 
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of treatment options in a short time.  Although diseases of companion animals do 
not have the same effect on society as those that affect humans, there is an 
increasing awareness of the benefits of companion animals in improving the 
health and well-being of human and a trend for demanding better treatment 
options at whatever cost.  Antiretroviral drugs and molecular tools are readily 
available to determine if drugs used to treat HIV could be repositioned to treat 
FeLV.  An important factor in assessing and instituting these potential treatments 
is adequate funding of well-designed studies that have sufficient numbers and 
controls to clearly define the treatment’s efficacy and potential toxicity. 
The goal of this dissertation is to identify and characterize compounds that 
may be useful in the treatment of FeLV. To do this, a FeLV vector system was 
used to identify compounds with anti-FeLV activity. Any compounds that 
demonstrated anti-FeLV activity were further characterized for the antiviral 
mechanism of action. Since some of the compounds identified also demonstrate 
anti-HIV activity, comparative studies were performed to compare the anti-HIV 
and anti-FeLV activities. The results described in this dissertation should help 
lead to the development of novel drugs that can be used to treat FeLV infection 
in domestic cats. 
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Table 1-1 Description of feline leukemia virus (FeLV) subtypes, their 
tropism, and prevalence in infected cats. 
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Figure 1-1.  Pathogenesis of FeLV showing common entry route of virus, sites of 
viral replication and pathological consequences of infection. 
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Chapter II 
Discovery of drugs that possess activity against feline leukemia virus 
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Mansky LM. Discover of drugs that possess activity against feline leukemia virus. 
Journal of General Virology. 2012; 93:900-905. Epub 2012 Jan 18. 
 
  20 
 
 
Introduction 
Feline leukemia virus (FeLV) is a highly transmissible retrovirus that 
causes significant morbidity and mortality in felids worldwide.  FeLV-infected cats 
succumb to diseases such as leukemias and lymphomas as well as secondary 
infections related to FeLV-induced immune suppression.  Infected cats transmit 
the virus through saliva, nasal secretions, coitus, as well as vertically from queen 
to kitten (Rickard, Post et al. 1969; Essex, Klein et al. 1971; Cattori, Tandon et al. 
2009).  These routes of transmission lead to a high prevalence of infected cats, 
especially in the stray cat population where the prevalence may be as high as 
43% (Rogerson, Jarrett et al. 1975).  Despite its prevalence and its associated 
morbidity and mortality, there are limited treatment options for FeLV infection.  
Currently, AZT is the only antiviral drug routinely used to treat FeLV, but its use is 
associated with significant side effects (Haschek, Weigel et al. 1990) including 
aplastic manifestations of FeLV.  Besides AZT, immunomodulators are used as a 
treatment for FeLV, however, these drugs are often cost-prohibitive and the 
efficacy of these drugs is limited (Tavares, Roneker et al. 1987; Hartmann, Block 
et al. 1998; Gingerich 2008).   Due to the lack of effective treatment options, 
many owners choose to euthanize or provide palliative care to infected cats. 
Among retroviruses, HIV-1 is the most extensively studied in terms of drug 
development. According to the FDA, there are approximately 25 drugs currently 
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approved for the treatment of HIV-1.   Although HIV-1 is a lentivirus and FeLV is 
a gammaretrovirus, there are enough similarities between the mechanisms of 
replication of the two viruses to indicate that anti-HIV-1 drugs may also inhibit 
replication of FeLV.  
 In order to expand the treatment options for feline leukemia, here we 
describe the anti-FeLV activity of four FDA-approved drugs: tenofovir, raltegravir, 
decitabine, and gemcitabine.  We hypothesize that While tenofovir and raltegravir 
are FDA approved for AIDS chemotherapy, decitabine (5-aza-2’-deoxycytidine) 
and gemcitabine (2’,2’-difluoro-2’-deoxycytidine), shown in Figure 3-1, are 
cytidine analogs used for the treatment of myelodysplastic syndrome (Garcia, 
Jain et al. 2010) and pancreatic cancer (Cerqueira, Fernandes et al. 2007; Wang, 
Lohman et al. 2009), respectively.  We recently demonstrated the ability of 
decitabine and gemcitabine to inhibit HIV-1 replication (Clouser, Patterson et al. 
2010; Clouser, Holtz et al. 2011).  In addition, recent studies have shown that 
tenofovir and raltegravir exhibit antiviral activity against, a related 
gammaretrovirus xenotropic murine leukemia related virus (XMRV) (Paprotka, 
Venkatachari et al. ; Singh, Gorzynski et al. ; Smith, Gottlieb et al.). Here we 
show that these drugs also inhibit FeLV replication in cell culture. 
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Results 
 Validation of single cycle infectivity assay using GFP-tagged FeLV.  A 
single cycle assay was used to examine the potential anti-FeLV activity of 
decitabine, gemcitabine, raltegravir, and tenofovir.  The relevance of this model is 
to act as a “first pass” assay to identify potential agents with anti-FeLV activity.  
To do this, a FeLV construct was designed to express GFP from an internal 
ribosomal entry site (Schafer and Squires) element that was inserted into the env 
gene.  Since this vector FeLV-GFP (Figure 2-1) lacks a functional env gene, 
vector replication is limited to one round of replication.  The single cycle aspect of 
this assay allows for the detection of agents that posses antiviral activity and 
eliminates compounding factors like re-infection and drug resistance that can be 
seen in vivo models.  To validate the activity of the FeLV-GFP vector and the 
ability of the assay to detect antiviral activity, the single cycle assay was 
performed using AZT, an antiretroviral used clinically to treat FeLV.  To do this, 
293T cells were cotransfected with FeLV-GFP and a vesicular stomatitis virus 
glycoprotein (VSV-G) envelope expression plasmid.  Cell culture supernatants 
were harvested and used to infect Crandell-Rees feline kidney (CRFK) cells that 
had been pretreated with the AZT concentrations indicated in Figure 2-2A.  The 
percent of infected cells was determined by flow cytometry using GFP expression 
as a marker for infection.  Figure 2-2A shows that AZT led to a concentration-
dependent decrease in the percentage of cells infected with FeLV, thereby 
validating the use of the FeLV-GFP assay to detect anti-FeLV activity. 
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 Decitabine, gemcitabine, tenofovir, and raltegravir inhibit FeLV infectivity 
in cell culture.  To test they hypothesis that decitabine, gemcitabine, tenofovir, 
and raltegravir can inhibit FeLV replication, the single cycle assay with FeLV-
GFP was performed as described. Figure 2-2B-2-2E show that individual 
treatment of target cells with each of the four drugs led to a concentration-
dependent decrease in FeLV infection, with raltegravir demonstrating the 
greatest antiretroviral potency.  Our observation that raltegravir has anti-FeLV 
activity confirms a recent observation (Cattori, Weibel et al.).  The concentrations 
required to reduce infection by 50% (IC50) are shown in Table 2-1 and 
demonstrate that decitabine, gemcitabine, and raltegravir have potent 
(nanomolar) anti-FeLV activity while tenofovir has micromolar anti-FeLV activity. 
 Tenofovir, raltegravir, decitabine, and gemcitabine have antiviral activity at 
concentrations that are not toxic in CRFK cells.  Each drug was examined to test 
the hypothesis that the concentrations that exert antiretroviral activity were not 
cytotoxic. None of the drugs induced cytotoxicity at the concentrations required to 
exert antiviral activity.  In fact, decitabine failed to induce toxicity even at 
concentrations 360-fold greater than the IC50 for antiviral activity. Similarly, 
tenofovir and raltegravir failed to induce toxicity at concentrations that were 10- 
and 280-fold higher than their IC50 values, respectively.  In contrast, gemcitabine 
induced cytotoxicity with a cytotoxic concentration 50 (CC50) of 230 nM, giving a 
selectivity index (SI = CC50/IC50) of 9.2 (Table 2-1).   
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Discussion 
FeLV is responsible for significant mortality in cats worldwide and despite 
both its prevalence and associated morbidity and mortality, treatment options for 
FeLV are extremely limited, associated with significant side effects, and can be 
cost-prohibitive for many cat owners.  In comparison to the development of novel 
therapeutics for FeLV, the development of drugs to treat HIV-1 has been more 
active.  Since both FeLV and HIV-1 have similar mechanisms of replication, 
drugs used to treat HIV-1 may be useful in the treatment of FeLV and therefore 
may be used to expand the available treatment options for FeLV.  
In this study, we developed a construct that was used to identify four FDA-
approved drugs that inhibit FeLV in cell culture.  Two of the drugs, tenofovir and 
raltegravir are used clinically to treat HIV-1 while the other two drugs, decitabine 
and gemcitabine, are used for the treatment of myelodysplastic syndromes and 
pancreatic cancer, respectively.  Furthermore, the antiviral activity of all four 
drugs was achieved at concentrations that were not cytotoxic. 
 Although both FeLV and HIV-1 are retroviruses, there is a possibility that 
the drugs may possess alternative mechanisms of action.  Previous studies have 
shown that differences in reverse transcriptase active sites among different 
retroviruses can affect susceptibility to NRTIs.  For example the YXDD motif in 
the active site of all retroviral reverse transcriptases (RT) plays a significant role 
in susceptibility to NRTIs.  Specifically, differences in the “X” position of this motif 
affect the ability of RT to incorporate nucleoside analogs containing modified 
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sugars (Poch, Sauvaget et al. 1989; Boyer, Gao et al. 2001; Operario, Reynolds 
et al. 2005; Jamburuthugoda, Santos-Velazquez et al. 2008).  HIV-1 and other 
lentiviruses have a methionine at the “X” position that enables incorporation of 
nucleoside analogs with modified sugars.  In contrast, structural studies show 
that a valine present at the “X” residue in FeLV and other oncoretroviruses 
restricts access of nucleoside analogs with a modified ribose.  Although 
gemcitabine has a modified ribose (fluorinated on the 2’ carbon), it is a potent 
inhibitor of FeLV replication (Figure 2-2).  However, the antiviral activity of 
gemcitabine may not necessitate its corresponding triphosphate to be a substrate 
of reverse transcriptase.  Instead, gemcitabine’s mechanism of action may be 
related to its ability to alter dNTP pools.  In support of this, previous studies have 
shown that retrovirus replication may be especially sensitive to changes in dNTP 
pools such that replication is inhibited prior to inhibition of cell cycle progression 
(Bebenek, Roberts et al. 1992). 
Since decitabine has an unmodified deoxyribose, it is not expected that 
the “Val” present in the FeLV active site would exclude its incorporation into viral 
DNA by reverse transcriptase.  Clinically, decitabine is used for its ability to be 
incorporated into DNA in place of dCTP where it binds to and irreversibly inhibits 
DNA methyltransferase. Its anti-HIV-1 activity has been attributed to its 
incorporation into viral DNA in place of dCTP by reverse transcriptase (Clouser, 
Patterson et al. 2010).  Once incorporated, it induces G-to-C mutations and this 
increase in mutant frequency correlates with its anti-HIV-1 activity.  However, 
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whether decitabine has the same mechanism of action in FeLV is not clear.  The 
fact that FeLV reverse transcriptase has a higher fidelity than HIV-1 RT suggests 
that decitabine could act by a mechanism distinct from HIV-1 (Operario, 
Reynolds et al. 2005).  
The anti-FeLV mechanisms of tenofovir and raltegravir are likely to be 
similar to what has been described for HIV-1.  Clinically tenofovir is given in the 
form of a prodrug where it is converted to an acyclic nucleoside phosphate which 
is an analog of adenosine 5’-monophosphate.  Once converted to the active 
diphosphate form, tenofovir is incorporated into viral DNA by reverse 
transcriptase where it acts as a chain terminator to inhibit further elongation of 
the viral DNA (Robbins, Srinivas et al. 1998; Kearney, Flaherty et al. 2004).  In 
contrast, raltegravir inhibits integration of the double stranded viral DNA that is 
produced by reverse transcription of the viral RNA genome (Beck-Engeser, Eilat 
et al. 2009; Reigadas, Andreola et al. 2010).    
In summary, we have demonstrated the anti-FeLV activity of four FDA-
approved drugs whose anti-HIV-1 activity has been previously described.  All four 
drugs exerted antiviral activity at concentrations examined with selectivity 
indexes of > 361.6 (decitabine), 9.2 (gemcitabine), > 10 (tenofovir), and > 285.7 
(raltegravir).  None of the drugs exhibited cytotoxicity within the therapeutic range 
tested, thereby warranting further investigation into their mechanisms of action as 
well as their suitability as treatments for FeLV (e.g., pharmacokinetics and 
pharmacodynamics studies).  Expansion of the available treatments for FeLV is 
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expected to significantly impact the morbidity and mortality of infected cats since 
current treatments have limited efficacy and are associated with serious side 
effects.  
 
Materials and Methods 
 Materials, cells and reagents.  Crandell-Rees feline kidney (CRFK) cells 
were obtained from Dr. Richard Van Deusen, National Veterinary Services 
Laboratory (Ames, IA), and 293T cells were obtained from American Tissue Type 
Culture (Manassas, VA).  DMEM was obtained from Mediatech (Manassas, VA).  
Gemcitabine was from Carbosynth (Berkshire, U.K), and decitabine was obtained 
from Moravek Biochemicals (Brea, CA).  The following reagents were obtained 
through the NIH AIDS Research and Reference Reagent Program, Division of 
AIDS, NIAID, NIH: (tenofovir, cat #: 10199) from (Division of AIDS, NAID); 
(raltegravir, cat #: 11680) from (Merck & Company, Inc); and (pEECC-FeLV, cat 
#: 105) from (Dr. James I. Mullins).  The pEECC-FeLV is a replication competent 
feline leukemia virus clone.  The internal ribosomal internal entry site (IRES) and 
the enhanced green fluorescent protein (GFP) gene sequence used to create the 
FeLV-GFP vector was from the plasmid pHIG (Clouser, Patterson et al. 2010) 
and was originally derived from pIRES2-eGFP (Clontech, Mountain View, CA). 
The vesicular stomatitis virus G protein (pL-VSV-G) envelope expression plasmid 
was obtained from Dr. Jane C. Burns (UC-San Diego).  CRFK cells and the 293T 
cells were maintained in DMEM supplemented with 10% fetal clone 3 (FC3) 
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serum from HyClone (Logan, VT) and penicillin/streptomycin (100 ug/mL and 100 
units/mL) at 37 ˚C in 5% CO2.  During drug treatment, cells were maintained in 
DMEM supplemented with 10% FC3 without penicillin/streptomycin. 
 Design and construction of the FeLV-GFP vector.  The FeLV-GFP vector 
was created by inserting the IRES-GFP sequence into the env gene of FeLV 
from the pEECC-FeLV plasmid.  To do this, the IRES-GFP sequenced was 
amplified by PCR using the following primers: 
5’ ATGCATACCATGGTGGCCAGGCTAGGG 3’ (forward) and  
5’ CCATGCATTTACTTGTACAGCTCGTCCATG 3’ (reverse),  
which included the Nsi I restriction site (underlined).  The pEECC-FeLV plasmid 
was digested with Nsi I restriction enzyme, removing a 615 bp sequence from 
env.  The linear pEECC-FeLV backbone was dephosphorylated with antarctic 
phosphatase.  The pEECC-FeLV backbone was gel purified using the Wizard SV 
Gel and PCR Clean-up system from Promega (Madison, WI) following the 
manufacturer’s instructions.  The ligation of the pEECC-FeLV backbone with the 
IRES-GFP insert was done at a 1:5 (plasmid backbone to DNA insert) molar 
ratio.  The ligation product was transformed into DH5α (E. coli) cells from 
Invitrogen (Carlsbad, CA) and plated onto Luria-Bertani (LB) agar containing 50 
µg/mL ampicillin.  Individual colonies were grown in LB broth containing 50 
µg/mL ampicillin and the DNA from these cultures was purified using Invitrogen’s 
PureLink Quick Plasmid Miniprep Kit (Carlsbad, CA).  DNA sequencing 
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(Functional Biosciences, Madison, WI) was done to verify the correct 
construction of the vector. 
 Transfection of 293T cells. FeLV-GFP plasmid (10 µg) and pL-VSV-G 
plasmid (1 µg) were cotransfected into 293T cells using the calcium phosphate 
coprecipitation method.  Twenty four hours after transfection, media was 
removed and replaced with 6 mL of fresh media.  Supernatant containing 
infectious virions was collected from cells 48 hours post-transfection and passed 
through a 0.2 µm filter.  The filtered supernatant was stored at -80 ˚C for later 
use. 
 Drug treatment and infection of CRFK cells. CRFK cells (65,000) were 
plated per well of a 12-well dish 24 hours prior to drug treatments.  Twenty-four 
hours later, the cells were treated with drug (decitabine, gemcitabine, tenofovir, 
or raltegravir) at the concentrations indicated in Fig. 2-2. Two hours after initiating 
drug treatments, cells were infected and then incubated at 37 ˚C for 24 hours. 
Twenty-four hours post-infection, the media was removed and replaced with 
fresh DMEM and the cells were then incubated for an additional 24 hours at 37 
˚C.  To analyze FeLV-infected cells, 48 hours post-infection, cells were 
trypsinized, centrifuged at 800 x g for 5 minutes and the cell pellets were 
resuspended in 2% paraformaldehyde in PBS containing 2% FC3.  Samples 
were analyzed by flow cytometry using a Becton Dickinson FACScan.  Samples 
were gated based on FSC vs. SSC to eliminate dead cells and GFP-expressing 
cells were detected in the FL1 channel.  The raw data was converted to relative 
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GFP expression by setting non-treated cells (0 nM) to 100% and multiplying the 
data for each individual treatment by the factor used to convert the non-treated 
group to 100. Uninfected cells were used to account for any non-specific signal in 
the FL1 channel.   
 Analysis of cytotoxicity.  CRFK cells (1.5 x 103) were plated per well of a 
96 well plate 24 hours prior to the initiation of drug treatment.  Cells were treated 
with drug (AZT, decitabine, gemcitabine, tenofovir, or raltegravir) for 24 hours at 
which time the media was replaced with fresh DMEM containing 10% FC3.  Cell 
viability was examined using Promega’s CellTiter-Glo kit according to the 
manufacturer’s instructions.  Briefly, cell viability was assessed 48 hours post 
drug treatment by adding a substrate that emits light at 570 nm in the presence 
of ATP.  Background luminescence was subtracted from the value obtained from 
each well.  The data were converted to relative luminescence by setting non-
treated cells (0 nM) to 100 and multiplying the data for each individual treatment 
by the factor used to convert the non-treated group to 100. 
 
 
 
Table 2-1.  In vitro cytotoxicity of decitabine, gemcitabine, tenofovir, and 
raltegravir in Crandell-Rees feline kidney (CRFK) cells.  CRFK cells were 
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incubated in the presence of drug for 48 hours. The IC50 values represent the 
concentration at which 50% of virus replication was inhibited, as determined for 
the data in Fig 2-2 with the 95% confidence interval indicated. CC50 values were 
determined using the Cell Titer-Glo Luminescent Cell Viability Assay (see 
Methods for details). 
 
 
 
Figure 2-1.  FeLV-GFP vector and model system for monitoring viral infectivity. 
(A) The FeLV vector, FeLV-GFP, is shown with the gfp gene inserted into the env 
gene.  The long terminal repeats (LTRs), gag and pol genes are indicated. (B) 
Single replication cycle assay performed with permissive Crandell-Rees feline 
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kidney (CRFK) target cells.  FeLV-GFP was co-transfected into 293T cells with a 
vesicular stomatitis virus glycoprotein G (VSV-G) envelope expression plasmid.   
Cell culture supernatants were harvested and used to infect CRFK target cells. 
Viral infectivity was monitored by measuring GFP expression using flow 
cytometry. 
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Figure 2-2.  Dose response of FeLV infectivity to decitabine, gemcitabine, 
tenofovir, and raltegravir.  CRFK cells were exposed to the indicated drug 2 
hours prior to infection with FeLV.  Infected cells were analyzed by flow 
cytometry.  Each data point represents the average of 3 independent replicates 
with the standard deviation indicated.  The molarity of the drug concentration 
range analyzed is indicated along the x-axis.  A)  Validation of assay using AZT.  
B) - E).  Analysis of decitabine, gemcitabine, tenofovir and raltegravir, 
respectively. 
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CHAPTER III 
 
INVESTIGATING THE MECHANISM OF ACTIVITY OF DECITABINE, 
GEMCITABINE AND CYCLOPENTENYL CYTOSINE AGAINST FELINE 
LEUKEMIA VIRUS 
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Introduction 
Over the years, there has been improvement in the treatment of 
hematological malignancies, solid tumors, and viral infections, such as human 
immunodeficiency virus type 1 (HIV-1), with the development of a specific class 
of drugs known as nucleoside analogs.  This special class of drugs is 
characterized for its ability to mimic natural nucleosides. Like naturally occurring 
nucleosides, nucleoside analogs are transported, activated, and incorporated into 
DNA.  Of the four natural nucleosides, dCTP is generally the lowest in 
abundance (de Korte, Haverkort et al. 1985), implicating that cytosine analogs 
could be an effective target for cancer therapy.  Some nucleoside analogs that 
have anti-cancer activity can also show antiviral activity at non-toxic 
concentrations however in some cases the antiviral mechanism of action may 
differ from the anti-cancer mechanism.  Two such cytosine analogs, gemcitabine 
and decitabine were previously shown to have anti-HIV-1 activity at non-cytotoxic 
concentrations (Clouser, Patterson et al. 2010; Clouser, Holtz et al. 2012).  Data 
suggested that these analogs worked by inducing viral mutations. Decitabine is 
phosphorylated to its triphosphate form in cells and is recognized by HIV-1 
reverse transcriptase and incorporated into viral DNA.  Once incorporated, it 
undergoes a conformational change creating a G-to-C mutation (Dapp, Clouser 
et al. 2009). Gemcitabine is also proposed to act as a viral mutagen, but instead 
of being incorporated into the viral genome by reverse transcriptase (RT), it may 
act as a ribonucleotide reductase inhibitor (Clouser, Patterson et al.).  This 
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enzyme is vital for the generation of deoxynucleotide triphosphates (dNTPs).  
Studies have shown that altering dNTP pool levels can lead to genomic 
mutations in retroviruses (Bebenek, Roberts et al. 1992; Mezei and Minarovits 
2006).  Similarly, we previously reported the susceptibility of FeLV to gemcitabine 
and decitabine (Greggs, Clouser et al. 2012). 
 In this study, the anti-FeLV activity of decitabine, gemcitabine, and a third 
cytosine analog, cyclopentenyl cytosine (CPEC) were examined (Figure 3-1).  
CPEC is a cytosine analog that inhibits deoxycytosine triphosphate (dCTP) 
synthetase, the enzyme responsible for synthesis of cytosine triphosphate (CTP) 
from uridine triphosphate (UTP), a key process involved in the generation of 
dCTPs, (Kang, Cooney et al. 1989; Verschuur, Van Gennip et al. 2000).  Unlike 
the broader activity of gemcitabine that acts on multiple dNTP pools, CPEC 
specifically targets the dCTP pool.  In this study, comparative analysis with HIV-1 
was done to investigate the antiviral activity and action of mechanism of 
decitabine, gemcitabine and CPEC. 
  
Results 
 CPEC possesses antiviral activity against FeLV. CPEC is a cytosine 
analog that has been shown to selectively decrease the levels of dCTP.  Its 
ability to inhibit CTP pools has led to its use for the treatment of cancer.  
Additionally, CPEC has been shown to have a broad-spectrum antiviral activity 
against viruses, including cytomegalovirus, influenza, parainfluenza, and 
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coronavirus, (De Clercq, Murase et al. 1991). CPEC was hypothesized to 
possess anti-FeLV activity.  Since retroviruses such as HIV-1 and FeLV have 
been shown to be susceptible to cytosine analogs, we examined the ability of 
CPEC to inhibit HIV-1 and FeLV replication using the single replication cycle 
assay (Figure 3-2A and 3-2B). Specifically, CPEC-treated or DMSO-treated 
MAGI cells were infected with vesicular stomatitis virus protein-G (VSV-G) 
psuedotyped FeLV and flow cytometry was used to detect GFP expression, 
which is used as an indicator of the percentage of infected cells.  
 The data revealed a concentration-dependent decrease in FeLV infectivity 
(Figure 3-4A).  Furthermore, this antiviral activity was unique to FeLV since 
CPEC failed to demonstrate anti-HIV-1 activity even at concentrations as high as 
1 µM.  While FeLV demonstrated an inhibitory concentration 50% (IC50) of 872 
nM (Figure 3-4A), this value could not be calculated for HIV-1.  Consistent with 
our previous studies, decitabine and gemcitabine demonstrated antiviral activity 
against FeLV with IC50 values of 1301 nM (Figure 3-11C) and 68 nM (Figure 3-
11E), respectively.  These IC50 values are higher than previously shown for 
decitabine and gemcitabine, which could be due to drug stability or drug lot 
variability.    
 The cytosine analogs decitabine, gemcitabine, and CPEC are active 
during reverse transcription.  To test the hypothesis that the antiviral target of 
decitabine, gemcitabine, and CPEC was reverse transcriptase, the time-of-
addition assay was performed using a single cycle replication assay (Hayouka, 
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Levin et al. ; Daelemans, Pauwels et al. 2011; Lara, Ixtepan-Turrent et al. 2011).  
In order to perform the time-of-addition assay, CRFK cells were infected and then 
treated with decitabine, gemcitabine or CPEC at specific time points post-
infection.  Infectivity was then monitored by flow cytometry, which was used to 
detect GFP expression. 
 In the time-of-addition assay, drugs that act at the point of reverse 
transcription should possess antiviral activity until 2-6 h post-infection.  
Compounds that target viral integration are expected to possess antiviral activity 
until about 8-10 h post-infection, beyond which there is a loss of activity. 
 Two control drugs, AZT, a nucleoside analog that inhibits reverse 
transcriptase (RT) and raltegravir, an integrase inhibitor were included in the 
analyses.  Consistent with other published data, AZT was less potent after 3 h 
post-infection while raltegravir had less activity after 8 h post-infection (Figure 3-
3).  The antiviral activity of decitabine declined after 3 h post-infection while 
gemcitabine’s antiviral activity declined after 2 h post-infection (Figure 3-3).  The 
antiviral activity of both drugs decreased at a time that is consistent with 
inhibitors of reverse transcription activity.  In contrast, the antiviral activity of 
CPEC declined as early as 2 h post-infection (Figure 3-3).  This early time point 
could suggest reverse transcription as a target, but is also in range for what has 
been seen for fusion inhibitors.  
 Antiviral activity of CPEC is not due to cytotoxicity.  The therapeutic 
mechanism of CPEC is known to target cellular factors, which could induce 
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cellular toxicity and lethality at high drug concentrations.  To test the hypothesis 
that the antiviral activity observed was not due to drug cytotoxicity, the cytotoxic 
effects of CPEC in both MAGI and the CRFK cell lines were examined.  As 
shown in Figure 3-5, only minimal cytotoxicity was seen at the highest 
concentration tested for antiviral activity (1 µM), where only 7%  and 15% of the 
cells shown signs of cytotoxicity to CPEC in MAGI and CRFK cell lines, 
respectively.  At the 1µM concentration, an antiviral activity of IC52 was observed  
as determined in MAGI cells (Figure 3-4A).  CPEC was found to have a cytotoxic 
concentration 50% (CC50) of 52 µM in MAGI cells and 6 µM in CRFK cells 
(Figure 3-5A and 3-5B, respectively).  The selectivity index (CC50/IC50), the cell 
culture equivalent to a therapeutic index, for CPEC with FeLV in MAGI cells was 
determined to be 59.6. Given this, the observed antiviral activity of CPEC could 
not be attributed to cellular toxicity. 
 CPEC dependent potentiation of cytosine analogs is not evident against 
FeLV infectivity. The cytosine triphosphate synthetase inhibitor, CPEC, 
decreases dCTP levels in cancer cells (Ford, Cooney et al. 1991; Verschuur, Van 
Gennip et al. 2000).  Since the cytosine analogs decitabine and gemcitabine 
have potent antiviral activity that appears to be due to their ability to compete 
with dCTP, we hypothesized that a CPEC-mediated decrease in dCTP levels 
would potentiate decitabine and gemcitabine's antiviral activity.  As shown in 
Figure 3-5C, CPEC did not potentiate the anti-HIV-1 activity of decitabine. 
Although there was an increase in antiviral activity with increasing concentrations 
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of CPEC, this increase was not statistically significant.  In contrast, CPEC 
significantly increased the anti-HIV-1 activity of gemcitabine.  The data 
demonstrated a significant effect of 800 nM CPEC on the potency of 20 nM 
gemcitabine (Figure 3-6E) with a p < .05 [F(2, 6) = 6.005, p = .0370]. Post-hoc 
comparison using the Tukey test indicated that the mean infectivity for 
gemcitabine 20 nM alone was significantly different from the CPEC 800 nM – 
gemcitabine 20 nM combination  (M diff = 38.56, 95% CI = 4.418 – 72.70).  While 
CPEC potentiated the anti-HIV-1 activity of gemcitabine, it had no effect on the 
anti-FeLV activity of gemcitabine. (Figure 3-6F).  As expected, CPEC had no 
effect on the antiviral activity of AZT, a thymine analog that competes with TTP, 
not CTP for incorporation into the viral DNA for both HIV-1 (Figure 3-6A) and 
FeLV (Figure 3-6B).  
 Gemcitabine minimally affects dNTP pool levels. Since both gemcitabine 
and CPEC are reported to effect dNTP levels (Kang, Cooney et al. 1989; 
Heinemann, Schulz et al. 1995; Verschuur, Van Gennip et al. 2000; Cerqueira, 
Fernandes et al. 2007; van Bree, Rodermond et al. 2008), we hypothesized that 
the dNTP levels would be imbalanced in cells that were treated with either 
gemcitabine or CPEC.  To test this, dNTPs were extracted from 5 x 106 CRFK or 
3 x 106 MAGI cells that were exposed to gemcitabine or CPEC for 4 h. The 
extracted dNTPs were then examined using liquid chromatography mass 
spectrometry.  The data revealed that 100 nM gemcitabine decreased dATP 
pools by 4.3-fold (p ≤ 0.001) in MAGI cells, whereas 800 nM CPEC, led to a 1.9-
  42 
fold increase (p ≤ 0.001) in dATP pools (Figure 3-7A).  No significant changes in 
the dCTP, dTTP or dGTP pools were detected in MAGI cells (Figure 3-7B – 3-
7D).  In CRFK cells, 500 nM and 5 µM of decitabine increased dATP pools by 
1.5- and 1.4-fold, p ≤ 0.05 and p ≤ 0.001, respectively (Figure 3-7E).  
Additionally, 500 nM and 800 nM of CPEC decreased dCTP pools by 2.3- and 
10.7-fold, respectively (Figure 3-7F), while no changes in dTTP or dGTP pools 
were detected in CRFK cells after treatment with any drug (Figures 3-7G and 3-
7H).  
  Decitabine, gemcitabine, and CPEC have no affect on the mutation 
frequency or mutation spectra of FeLV.  Previous studies have shown that 
decitabine and gemcitabine act as viral mutagens to decrease viral replication, a 
process known as lethal mutagenesis (Penn 1987; Clouser, Patterson et al. 
2010; Clouser, Holtz et al. 2011; Clouser, Holtz et al. 2012).  Additionally, the 
ability of CPEC to alter dNTP pools suggests that it may induce mutations in the 
retroviral genome.  These observations let to the hypothesis that decitabine, 
gemcitabine and CPEC can increase FeLV mutation frequency and spectra by 
incorporation and induction of G-to-C mutations (i.e., decitabine) or by causing 
imbalances in cellular dNTP pools (i.e., gemcitabine and CPEC).  To examine 
the effect of decitabine, gemcitabine, and CPEC on the mutation frequency of 
FeLV, we used Illumina® next-generation DNA sequencing to sequence 
integrated FeLV proviral DNA from cells that had been treated with or without 
decitabine, gemcitabine, or CPEC.  Approximately 17.5 million sequences were 
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examined in order to detect drug-induced changes in the viral mutation 
frequency. Unexpectedly, none of the drugs increased the FeLV mutation 
frequency (Figure 3-8A) [F(3,8,) = 0.6368, p = 0.6121].  Furthermore, results from 
our mutation spectra analysis revealed no significant changes in the types of 
mutations that occurred when comparing no drug to each of the drug treatments 
(Figure 3-8B).  
 Decitabine, gemcitabine, and CPEC do not affect the late stages of the 
viral life-cycle. While the time-of-addition assay indicated that decitabine, 
gemcitabine, and CPEC target viral replication at the point of reverse 
transcription, it is possible that the compounds could also have antiviral activity at 
other steps in the life cycle. To test the hypothesis that the late steps in the FeLV 
replication cycle (i.e., viral RNA transcription, translation, viral RNA and protein 
trafficking, virus assembly and release) are not affected by decitabine, 
gemcitabine and CPEC, we examined if these drugs could also target viral 
replication at a post-integration step.  Briefly, the assay involves the production of 
virus in the presence or absence of drug (decitabine, gemcitabine, or CPEC) at 
approximately the IC80 values, with the exception of CPEC where the IC50 was 
used because this was the highest IC value attainable with CPEC without 
significant cytotoxic effects.  The virus was then used to infect target CRFK cells 
and flow cytometry was used to examine the percentage of infected cells. Figure 
3-9 shows that virus produced in the presence of decitabine, gemcitabine, and 
CPEC led to the same percentage of infected cells as virus produced in the 
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presence of the DMSO control. This finding indicates that each of these drugs 
exerts antiviral activity prior to viral production. This finding is consistent with the 
data generated with the time-of-addition assay (Figure 3-3), which indicated that 
each of these drugs act at or before reverse transcription. As a negative control, 
we used AZT, a nucleoside reverse transcriptase inhibitor whose antiviral activity 
is limited to the reverse transcription phase of the viral life cycle. As expected, 
when compared to no drug (DMSO solvent only), AZT did not have antiviral 
activity in the target cells when infected with virus that was produced in the 
presence of drug (Figure 3-9).  Comparable levels of GFP expression were 
observed in all cells regardless of the drug treatment, indicating that the 
transfection efficiency were relatively consistent (Figure 3-10). 
 The retroviral YXDD motif does not dictate susceptibility of viral replication 
to decitabine. Previous studies have demonstrated that specific amino acid 
motifs within the active site of reverse transcriptase affect the susceptibility of 
viral replication to nucleoside analogs. For example, the “X” position of the YXDD 
motif, a motif that is present in all retroviruses, plays a significant role in the 
ability of RT to incorporate nucleoside analogs that contain modified sugars 
(Poch, Sauvaget et al. 1989; Boyer, Gao et al. 2001; Operario, Reynolds et al. 
2005; Jamburuthugoda, Santos-Velazquez et al. 2008).  HIV-1 and other 
lentiviruses have a methionine (M) in the “X” position and are susceptible to the 
cytosine analog lamivudine (3TC). In contrast, oncoviruses like FeLV, and some 
drug resistance HIV-1 mutants, have a valine (V) in the “X” position, are less 
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susceptible to 3TC.  For example, wild type HIV-1 which has the Y[M]DD motif is 
susceptible to the nucleoside analog 3TC. However, the M184V (Tisdale, Kemp 
et al. 1993; Gallant 2006; Jamburuthugoda, Santos-Velazquez et al. 2008) 
mutation, which changes the Y[M]DD motif to Y[V]DD, is resistant to 3TC. Since 
the YXDD motif is known to affect susceptibility of retroviruses to nucleoside 
analogs, we examined if the “X” position within the YXDD motif affected 
susceptibility of viral replication to decitabine, gemcitabine, and CPEC.    To do 
this, we compared wild type FeLV, which has a valine in the “X” position of the 
YXDD motif, to a mutant FeLV where the valine was replaced by a methionine, 
making the YXDD motif resemble wild-type HIV-1. 
 Consistent with previous reports, wild type FeLV demonstrated resistance 
to 3TC (Operario, Reynolds et al. 2005). However, the FeLV-YMDD mutant 
displayed susceptibility to 3TC, with an IC50 value of 8.3 µM (Figure 3-11A and 3-
11B, respectively).  A cytotoxic analysis of 3TC confirmed that the apparent 
antiviral activity was not due to cytotoxicity in the CRFK cells (Figure 3-12).  We 
next examined the effect of the YXDD motif on the susceptibility of FeLV to 
decitabine and gemcitabine, two cytosine analogs with potent anti-HIV-1 activity 
(Clouser, Patterson et al. 2010; Clouser, Holtz et al. 2012).  It was observed that 
the wild-type FeLV and the FeLV-YMDD mutant displayed comparable 
susceptibilities to decitabine. (Figure 3-11C and 3-11D, respectively). Figures 3-
11E and 3-11F show that the wild-type and Y[M]DD mutant had similar 
susceptibility to gemcitabine.  In contrast, wild-type and the Y[M]DD mutant 
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demonstrated a significant difference in susceptibility to CPEC. Specifically, the 
Y[M]DD mutant displayed a 1.8-fold decrease in the IC50 value compared to wild-
type (Figures 3-11G and 3-4A, respectively).  
 
Discussion 
 The Retroviridae is a diverse family that shares similarities in genetic 
organization, mechanism of replication, and all utilize a high mutation rate to 
generate genomic diversity.  These similarities give rise to the potential for the 
use of one drug to inhibit the replication of more than one retrovirus.  This is 
particularly useful when examining potential treatments for FeLV, a virus that is 
not as well characterized as HIV-1. 
 The feline gammaretrovirus, feline leukemia virus (FeLV), is associated 
with morbidity and morality of companion felines (Hosie, Robertson et al. 1989; 
Bandecchi, Matteucci et al. 1992; Lutz, Addie et al. 2009) and wild felines 
(Gardner and Luciw 1989; Brown, Cunningham et al. 2008).  In companion 
felines, once infected there are limited treatment options and the ones that are 
available are often cost prohibitive and/or ineffective.  Preventatively, the option 
of vaccination is an affordable option, but the vaccines do not offer sterile 
immunity, so vaccinated cats that become infected can pass the infection to 
another susceptible cat.  Furthermore, it is general practice that the vaccine is 
usually reserved for cats thought to be at high risk, such as multi-cats household 
and catteries. 
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 There is only limited knowledge involving the treatment of FeLV with the 
use of antiretrovirals.  Being related to HIV-1, it is plausible that drugs used to 
treat HIV-1 will be useful against FeLV.  Previously, we were able to identify the 
anti-FeLV activity of two anti-cancer nucleoside analogs decitabine and 
gemcitabine, and two anti-HIV-1 drugs tenofovir (nucleotide analog) and 
raltegravir (integrase inhibitor) (Greggs, Clouser et al. 2012).  In this study, we 
examined the mechanism by which they elicit this antiviral activity.  In addition to 
decitabine and gemcitabine, we also examined the anti-FeLV activity of CPEC, a 
cytosine analog that we predicted may have anti-FeLV activity.  Although both 
FeLV and HIV-1 belong to the same family, it is possible for these drugs to inhibit 
viral infectivity through different mechanisms.  For example, nucleoside analogs 
have been shown to inhibit HIV-1 replication by at least three distinct 
mechanisms: 1) binding directly to the active site of reverse transcriptase to 
inhibit the enzyme, 2) inhibiting RT by binding to hydrophobic pockets distant to 
the active site, and 3) enhancement of viral mutagenesis.    
 The data in this study, particularly the results from the time-of-addition 
assay, support that decitabine, gemcitabine and CPEC exhibit potent anti-FeLV 
activity that targets the reverse transcription phase of the retroviral life cycle. 
Specifically, the data generated in the time-of-addition assay supported that each 
drug inhibited viral replication at the point of reverse transcription or earlier 
(Figure 3-3).  While gemcitabine did demonstrate a reduction in infectivity an 
hour earlier than the AZT control, the difference in the timing of activity could be 
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a result of differences in the amount of time required for the drug to be converted 
into its active form (Daelemans, Pauwels et al. 2011) or that gemcitabine has 
more than one mechanism of action.  Furthermore, the drugs had no inhibitory 
activity on virus production (Figures 3-9, and 3-10 and Tables 3-1 and 3-2). In 
contrast, the cytosine analog CPEC began to lose antiviral activity as early as 2 
h.  This is generally within the time range observed with early phase inhibitor like 
fusion or entry inhibitors (Hayouka, Levin et al. ; Daelemans, Pauwels et al. 
2011).  However, there is no known mechanism that would suggest that 
nucleoside analogs have the structural capability to act as either an entry or 
fusion inhibitor.  Further investigation may be needed to completely elucidate the 
implications of the data. The findings from the time-of-addition assay are 
supported by the producer cell assay that showed none of the compounds 
possess any activity on the late phase (post integration) of the retroviral life cycle 
(Figures 3-9, and 3-10 and Tables 3-1 and 3-2). 
 Based on structure of the drugs, known antiviral and/or anticancer 
activities, and the results from the time-of-addition assay, we hypothesized that 
the drugs inhibited reverse transcription.  There are two potential ways that the 
drugs can target reverse transcription: 1) induce lethal mutagenesis, 2) inhibit 
production of double stranded viral DNA either through direct inhibition of RT or 
through the inhibition of cellular dNTP production. 
 The DNA sequencing data presented here do not support lethal 
mutagenesis as the primary antiviral mechanism of action.  Although gemcitabine 
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induced changes in dNTP levels, the changes were not large enough to suggest 
that the dNTP levels were too low to support reverse transcription. Thus, the data 
presented here is most consistent with direct inhibition of reverse transcriptase.  
The sequencing data for decitabine also suggests that its mechanism of activity 
may primarily involve a direct inhibition of FeLV reverse transcriptase.  In 
contrast, the changes induced by CPEC treatment do suggest that this drug acts 
by limiting the availability of dCTP for reverse transcription.  Due to its structure, 
CPEC is not believed to behave as a substrate for reverse transcriptase.  CPEC 
resembles cytidine in the RNA synthesis pathway, which is evident in the 
phosphorylation and activation of CPEC (Bierau, van Gennip et al. 2006; 
Schimmel, Gelderblom et al. 2007).  Examination of the late phase of the viral life 
cycle suggests that RNA synthesis/processing and virus production was not 
directly targeted.   
 To further examine the mechanism by which the drugs inhibit FeLV, we 
examined if the retroviral motif YXDD affected susceptibility of viral replication to 
the cytosine analogs, based on increase in susceptibility to the cytosine analog 
3TC seen with HIV-1 that has the phenotype Y[M]DD; and a decrease in 
susceptibility to 3TC when the methionine is mutated to a valine.  With the valine 
being found in the wild-type FeLV, the data show that mutation of this well-known 
resistance phenotype did not affect FeLV's susceptibility to decitabine nor 
gemcitabine.  These data suggest that this particular residue is not a primary 
participant in drug susceptibility of FeLV to decitabine or gemcitabine.  In 
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contrast, susceptibility to CPEC does seem to be affected by mutation in this 
residue.  Knowing that CPEC is an unlikely candidate for reverse transcriptase 
(RT), it is probable that the lower fidelity seen in RTs that posses the Y[M]DD 
phenotype could explain the shift in susceptibility to CPEC. 
 In summary, the anti-FeLV activity of three cytosine analogs – i.e., 
decitabine, gemcitabine, and CPEC – has been demonstrated.  We found that 
CPEC had anti-FeLV, but not anti-HIV-1 activity.  It is important to mention that 
as nucleoside analogs, all three of the nucleoside analogs examined were active 
during the early phase of the FeLV retroviral life cycle, with reverse transcription 
being the most likely target.  This suggests that CPEC is effective in reducing 
dCTP pool levels in the CRFK cell lines, and did not demonstrate a significant 
decrease in dCTP in the MAGI cell line. The data also suggests that these 
cytosine analogs, though shown to have mutagenic properties in HIV-1, may 
possess a unique mechanism for inhibiting FeLV replication. 
 
Material and Methods 
 Cell lines, plasmids, and compounds. Crandell-Rees feline kidney (CRFK) 
cells were obtained from Dr. Richard Van Deusen (National Veterinary Services 
Laboratory, Ames IA, USA), U373-MAGI-CXCR4 (MAGI) cells were obtained 
from the AIDS Reagent Program (from M. Emerman), and the 293T cells were 
obtained from the ATCC. Decitabine (catalog # M1774) was obtained from 
Moravek and gemcitabine (product # ND04237) was obtained from Carbosynth.  
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Cyclopentenyl cytosine (CPEC; NSC. # 375575-R) was obtained from the 
National Cancer Institute. Raltegravir (catalog # 11680, from Merck & Company, 
Inc), zidovudine (AZT; catalog # 3485), lamivudine (3TC; catalog # 8146), and 
pEECC-FeLC (catalog # 105) were obtained from the NIH AIDS Research and 
Reference Reagent Program, Division of AIDS, NIAIDS.  pEECC-FeLV is a 
replication-competent FeLV clone.  The IRES and the EGFP gene sequence in 
the FeLV-GFP vector were from the plasmid pHIG (Clouser et al., 2010) and 
were originally derived from pIRES2-EGFP from Clontech (Mountain View, CA).  
The VSV-G protein (pL-VSV-G) envelope expression plasmid was obtained from 
Dr. Jane C. Burns (University of California, San Diego, CA, USA). The HIV-1 
vector contains the IRES and the EGFP gene sequence, derived from pIRES2-
EGFP and a HSA gene sequence, derived from pNL4-3.HSA-R+.E-; and has 
been previously described (Dapp, Clouser et al. 2009). 
 Cell Culture. CRFK and 293T cells were maintained in Dulbecco's 
Modified Eagle's Medium from Mediatech, and were supplemented with 10% 
fetal clone 3 (FC3) serum (HyClone) and penicillin/streptomycin (100 mg/ml and 
100 U/ml, respectively).  U373-MAGICXCR4 were maintained in Dulbecco's 
Modified Eagle's Medium from Mediatech, and was supplemented with 10% FC3 
(HyClone), 0.2 mg/ml neomycin, 0.1 mg/ml hygromycin B, and 1.0 ug/ml 
puromycin.  All cells were maintained at 37ºC in 5% CO2. 
 Transfection of 293T cells. The FeLV-GFP plasmid (10 µg) or the HIV-1 
plasmid (10 µg) was cotransfected with VSV-G plasmid (1 µg) on to 293T cells 
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using the calcium phosphate coprecipitation method. Twenty-four hours after 
transfection, the medium was removed and replaced with fresh medium (6 ml). 
The supernatant containing infectious virions was collected from cells 48 h post-
transfection and passed through a 0.2 µm filter to remove cellular contaminants.  
The filtered supernatant was stored at -80ºC for later use. 
 Flow cytometry. Paraformaldehyde-fixed cell samples were analyzed by 
flow cytometry using a Becton Dickinson FACScan. Gating based on FSC vs 
SSC was used to eliminate dead cells, and GFP-expressing cells were detected 
in the FL1 channel. Relative GFP expression was calculated by setting non-
treated cells (0 nM) to 100% and multiplying the data for each treatment by the 
factor used to convert the non-treated group to 100. Background signal was 
accounted for by subtracting out the data from uninfected cells. 
 Analysis of cytotoxicity. To examine the cytotoxic activity of drug (CPEC, 
3TC, or CPEC in combination with decitabine, gemcitabine, or AZT), CRFK cells 
(1.5 x 103) or MAGI cells (4.5 x 103) were plated in each well of a 96-well plate 24 
h prior to the initiation of drug treatment. Cells were treated with drug for 24 h, 
after which the cell medium was removed and replaced with fresh DMEM 
containing 10% FC3. For the CPEC only treatments, the cells were incubated 
with drug for 48 h prior to the media change. For CPEC-drug (AZT, decitabine, 
gemcitabine) combination, the cells were pre-incubated with CPEC 24 h prior to 
drug treatment. Promega CellTiter-Glo kit was used according to the 
manufacturer's instructions to monitor cell viability. Background luminescence 
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was subtracted from the value obtained from each well. The data was converted 
to relative luminescence by setting the non-treated cells (0 nM) to 100 and 
multiplying the data for each individual treatment by the factor used to convert 
the non-treated group to 100. 
 Time-of-addition assay. CRFK cells (3.5 x 104) were plated into each well 
of a 24-well plate 24 h prior to viral infection. At time point zero (t=0), the cells 
were infected with a titer of virus to yield approximately 20% ± 10% infectivity.  
Drug (decitabine, gemcitabine, CPEC, raltegravir, or AZT) was added to 
designated wells corresponding to a specific time point (0, 2, 3, 4, 6, 8, 10, 12, 
14, 16, and 24 h).  The medium was then removed and replaced with fresh 
DMEM 24 h post-infection. After the media change, the 24 h time point was 
treated with drug. Each sample was trypsinized, centrifuged at 1,200 g for 5 min 
and the cell pellets were resuspended in 2% paraformaldehyde in PBS with 2% 
FC3 48 h post-infection. These samples were then analyzed by flow cytometry 
for GFP expression. The data is interpreted by looking for the time point where 
the drug starts to decrease potency. This was interpreted by a trending rebound 
of infectivity above baseline, which is illustrated by the point of inflection of the 
data points. As a standard of measure, two characterized control drugs, AZT and 
raltegravir, were included. AZT is a nucleoside analog that inhibits RT, and 
raltegravir is a integrase inhibitor. Other investigators have found the point of 
inflection for drugs that act during reverse transcription to range from 2 - 6 h and 
drug acting as integrase inhibitors ranging from 8 - 10 h (Hayouka, Levin et al. ; 
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De Clercq, Yamamoto et al. 1992; Daelemans, Pauwels et al. 2011; Lara, 
Ixtepan-Turrent et al. 2011). In this assay, the time point of decline of antiviral 
activity was defined by the time point of inflection where the virus increased 
above baseline. 
 Drug potentiation assay. MAGI cells (3.5 x 104) were plated into each well 
of a 24-well plate 48 hours prior to viral infection, after which the cells began a 24 
h pretreatment with CPEC. After the pretreatment, the cells were exposed to 
drug (decitabine, gemcitabine, AZT) for 2 h, after which they were infected with 
FeLV-GFP with a titer of virus to yield approximately 20% ± 10% infectivity. The 
medium was then removed and replaced with fresh DMEM 24 h post-infection. 
After the media change, the 24 h time point was treated. Each sample was 
trypsinized, centrifuged at 1,200 g for 5 min and the cell pellets were 
resuspended in 2% paraformaldehyde in PBS with 2% FC3 48 h post-infection. 
The samples were then analyzed for GFP expression by flow cytometry. 
Statistical analysis was done using the GraphPad Prism program. For each drug, 
statistical significance was determined using a one-way ANOVA with a Tukey 
post-test comparing the drug only to each CPEC – drug combination. 
 Assay for late phase antiviral activity. The FeLV-GFP plasmid (10 µg) and 
VSV-G plasmid (1 µg) were cotransfected into 293T cells using the calcium 
phosphate coprecipitation method. Twenty-four hours after transfection, the 
medium was removed and replaced with fresh medium, with or without drug 
(AZT, decitabine, gemcitabine, or CPEC). The drug concentration used was 
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approximately the IC80 – IC90, with the exception of CPEC, where the 
concentration used was approximately the EC50. The supernatant was collected 
24 h post treatment and 25 µl was used to infect target CRFK cells that were 
plated 24 h prior to a density of 6.5 x 104 cells per well on a 12-well plate. The 
transfected 293T cells were trypsinized, centrifuged at 1,200 g for 5 min and the 
cell pellets were resuspended in 2% paraformaldehyde in PBS with 2% FC3. 
These samples were then analyzed by flow cytometry for GFP expression.  The 
target cells underwent a medium change 24 h post-infection, and 48 h post 
infection they were also trypsinized, pelleted, and resuspended in 2% 
paraformaldehyde in PBS with 2% FC3. These samples were then analyzed by 
flow cytometry for GFP expression. Transfected 293T (producer) cells that were 
used to produce FeLV in the presence of drug were analyzed by flow cytometry. 
Flow cytometry was also used to analyze the infected CRFK (target) cells. The 
relative GFP expression for both the transfected producer (293T) cells and the 
infected target (CRFK) cells sample were calculated by setting no drug to 100% 
and multiplying the data for each individual treatment by the factor used to 
convert the non-treated group to 100%.  
 Analysis of FeLV mutation spectra by Illumina DNA sequencing. CRFK 
cells (2 x 105) were plated into each well of a 6-well plate 24 h prior to viral 
infection. The cells were pretreated with drug (decitabine or gemcitabine) for 2 h 
prior to viral infection; CPEC had a 24 h pretreatment time. After the 2 h or 24 h 
pretreatment, the cells were infected with FeLV-GFP to a MOI of 2. The virus 
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used for infections was pretreated with DNAse I (20 U/ml) for 1.5 h at 37ºC to 
eliminate plasmid contamination. The medium was removed and replaced with 
fresh DMEM 24 h post infection. The cells were trypsinized and centrifuged at 
1,200 g for 5 min. Cell pellets were used for genomic DNA extraction according 
to the manufacturer's instructions of ZymoBeadTM Genomic DNA Kit (Zymo 
Research). PCR was then used to amplify proviral regions of gag, pol, env, and 
two segments of gfp genes. These primers were specifically designed for 
Illumina® next-generation sequencing. The primers contained 2 degenerate 
bases to normalize reaction initiation and a barcode (underlined) on the forward 
primer only:  
5'NNTTTGGATCAACCAACCTGGGACGACT3' and 
5'NNAATGACATTGGGCAGCTGGGTT3' (gag, p27), 
5'NNTTTGGTCCAGAAATAGGACTGTCAGGGCA3' and 
5'NNAGCCAGCAAGAGGTCATCTACA3' (pol, reverse transcriptase), 
5'NNTTTGGTCCCGACAATCTCAAACAGGGT3' and 
5'NNTCGGTGGCATTTAAGGCTAGGT3' (env, gp 70), 
5'NNTTTGGTTCTTCAAGGACGACGGCAACT3' and 
5'NNGGCCATGATATAGACGTTGTGGCT3' (gfp 1), 
5'NNTTTGGAGGTGAACTTCAAGATCCGCCA3' and 
5'NNATGTGATCGCGCTTCTCGTT3' (gfp, 2).  
 The entire primer set is listed in Table I-1 of Appendix I. A plasmid control 
also underwent PCR to monitor PCR generated background mutation. PCR 
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reactions were done in triplicate for each amplicon, with respect to treatment and 
internal replication using the high fidelity Phusion Hot Start II polymerase 
(Finnzymes). Each internal PCR replication was pooled for each treatment and 
gel purified to remove primers and genomic DNA. The gel band was excised and 
cleaned using the Wizard SV Gel and PCR Clean-up System (Promega). The 
PCR amplicons were ligated into pGEM-T vector using the pGEM®-T and 
pGEM®-T Easy Vector Systems (Promega), according to the manufacturer's 
instructions, and transformed into DH5α (Escherichia coli). Individual colonies 
were isolated, expanded, and the DNA plasmid recovered by Invitrogen PureLink 
Quick Plasmid Miniprep kit. DNA samples for each amplicon was quantified by 
Quant-iT™ PicoGreen® dsDNA Assay kit (Invitrogen) for an equimolar pooling 
between samples to a total concentration of 3 µg.  
 The samples were submitted to University of Minnesota BioMedical 
Gemonics Center where the quality of the DNA was assessed using a 
fluorimetric PicoGreen assay.  In order to pass quality control, prior to library 
construction, the sample must have a quantity greater than 1 µg. Then 1 µg of 
the sample was used for library creation using the Illumina's Truseq DNA Sample 
Preparation Kit (cat#: FC-121-2001, see www.illumina.com for kit content and 
methods).  Library generation involved fragmenting 1 µg of genomic DNA using 
Covaris ultrasonic shearing and repairing the ends prior to ligating adaptor and 
index sequences.  Caliper XT (see www.perkinelmer.com for methods) was used 
to selects fragments of an average of 400 base pairs.  The library was then 
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amplified using 10 cycles of PCR and validated using capillary electrophoresis 
and quantified by the fluorimetric PicoGreen assay and/or Kapa Q-PCR.  
 For cluster generation, the library was hybridized to a paired end flow cell 
where individual fragments are clonally amplified by bridge amplification onboard 
the MiSeq system.   After clustering, sequencing was conducted using Illumina's 
SBS chemistry.  After read 1 was performed, a 6 base pair index read was 
performed. Lastly, the library fragments were re-synthesized in the reverse 
direction and sequenced from the opposite end of the read 1 fragment.  For 
primary analysis and de-multiplexing, Base call (.bcl) files for each cycle of 
sequencing are generated by Illumina Real Time Analysis (RTA) software.  The 
base call files are de-multiplexed and then converted to index specific fastq files 
using the MiSeq Reporter software on instrument (Please visit www.illumina.com 
for further details), after which the data was process for bioinformatics.  
 Data analysis began with pre-processing and running quality control with 
the Fastqc program.  The adapter sequencing attached to the amplicons were 
trimmed using the Fastq-mcf program.  Further processing involved 
demultiplexing the data, leaving more than half (9,641,870 of 17,711,281) of the 
reads unmatched to any barcode. The presence of a PhiX spike accounted for 
some to this loss of sequencing depth. Demultiplexing was performed using 
Fastq-multx program.  Paired end reads (3' forward and 5' reverse complement) 
were joined into a single read using Fastq-join program.  Two-thirds of each 
sample were joinable, and the reads that did not overlap were excluded.  A 6 bp 
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overlap and a 5% maximum difference between the two reads were the 
constraints for joining.  The Bowtie2 program was used to align each viral loci to 
the reference sequence at an overall acceptable rate of 99.45 - 93.04%.  The 
extreme edge base-pair of each loci were excluded due to a significant 
degradation in mapping quality. The Samtools were used to produce pileup files 
that detailed the nature of the alignment for each read in accordance to the 
reference database. These pileup files were used to compute mutations 
frequency and mutation spectra.  
 Mutation spectra were analyzed by computing the types of mutations that 
occurred within each viral loci per drug treatment.  The primary computation was 
custom-designed with the Phython program.  The strategy was to quantify 
mutations as a matrix of ‘starting nucleotide’ and ‘ending nucleotide.’  For the 
preliminary analysis the R was used to compute whether the spectra of mutations 
were different between drug treatments versus the no drug control.  The mutation 
matrix was converted to a proportion matrix, and the distance score between 
each pair of matrices was computed.  For the final analysis, the number for each 
type of base pair change was quantified and compared to no drug.  The final 
statistical analysis was done using the GraphPad Prism program. For each drug, 
statistical significance was determined using a one-way ANOVA with a Tukey 
post-test comparing the no drug to each drug treatment. 
 Mutation frequency was analyzed by computing mutation per base-pair 
sequenced using the same custom-designed program used for the mutation 
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spectra.  The mutation frequency of each viral loci for each drug treatment were 
compared to that of no drug control.  The R was used to compute whether 
mutation rates per locus (mutations/read mapped) were higher in drug versus 
control.  The data was preliminarily analyzed using a T-test one-tailed.  For the 
final analysis, the number for each base pair change was quantified and divided 
by the number of base pair sequenced for each drug treatment to calculate the 
mutation frequency.  The frequency of each drug treatment was compared to that 
of to no drug control.  The final statistical analysis was done using the GraphPad 
Prism program. For each drug, statistical significance was determined using a 
one-way ANOVA with a Tukey post-test comparing the no drug to each drug 
treatments.  
 dNTP Pool analysis. CRFK cells (6 x 106) or MAGI cells (3.5 x 106) were 
split between two 10 cm culture dishes per treatment group 16 - 24 h prior to 
drug treatment. The cells were treated with drug (AZT, decitabine, or 
gemcitabine) for 4 h to simulate the 2 h pretreatment of the infection assay and 2 
h for reverse transcription to take place (Daelemans, Pauwels et al. 2011). The 
CPEC treatments underwent a 24 h pretreatment prior to dNTP extraction. After 
the 4 h or 24 h drug incubation, the cells were trypsinized and centrifuged at 
1,200 g for 5 min.  
 The cell pellet was resuspended in 1 ml of ice cold PBS. They were 
counted and 5 x 106 (CRFK) or 3 x 106 (MAGI) cells were removed for dNTP 
extraction. These cells were centrifuged at 1.2 g for 5 min and PBS removed 
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from pellet. The pellet was then resuspended in 500 µL 65 % methanol 
containing 10 µM of the internal standard 5'-Iodo-2'dCTP (IdCTP), purchased 
from TriLink BioTechnologies (San Diego, CA). The cell suspension was 
vigorously vortexed for 2 min and stored at -80C overnight to precipitate proteins. 
After the 24 h incubation, the cells were centrifuged at 14,000 g for 3 min. The 
supernatant was collected and underwent speed-vacuum centrifugation to 
remove the methanol. The dried pellet was submitted for ion-pair based liquid 
chromatography-tandem mass spectrometry (LCMS-MS), utilizing the 
hexylamine ion-pair agent system.   
 The LCMS-MS was performed using an Agilent 1260 HPLC couple with 
an AB SCIEX QTRAP 5500 mass spectrometer.  To analyze the samples, an 
electrospray source was operating in positive and negative mode polarity 
switching. The source and parameters were set to the following: curtain gas: 20; 
CAD gas: medium; ion spray voltage: 4500; temperature: 600°C; gas1: 45; and 
gas 2: 45.  Deoxynucletides and internal standard (IS) were analyzed using 
multiple reaction monitoring (MRM) using the parameters listed in Table II-1 
(Appendix II).  Each dNTP was distinguishable by its unique mass post 
fragmentation.  Figure II-1 illustrates the fragmentation sites for each dNTP and 
IS (Appendix II). 
 The samples were separated using a 150mm × 3.9 mm Waters XTerra 
MS C-18 column (5 µm) with a mobile phase of 5 mM hexylamine containing 
0.5% diethylamine in water (pH 10, adjusted with acetic acid; mobile phase A) 
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and 50/50 water/acetonitrile (mobile phase B) with a flow rate of 0.3 ml/min 
(Zhang, Tan et al. 2011).  Analytes were eluted using a linear gradient of 0% to 
30% B over 30 min. The column was then washed with mobile phase B (95%) for 
3 min and re-equilibrated with mobile phase A (100%) for 15 min. Each LCMS-
MS run was exported into MultiQuant (AB SCIEX), which was used to calculate 
peak areas.  An example chromatograms for dATP, dCTP, dTTP, and the IS are 
illustrated in Figure II-2 A of Appendix II. Because dGTP has a lower peak than 
the other dNTP, a separate chromatogram is usually illustrated (Figure II-2 B of 
Appendix II).  Data was interpreted as integrated peak area, and normalized to 
the internal standard, 5-iodo-2'-dCTP (IdCTP) for mass spectrometry calibration, 
then normalized to no drug (DMSO only control). This data was analyzed using 
one-way ANOVA, with a Tukey post-hoc test (Graphpad Prism).  
 Generation of the FeLV YXDD reverse transcriptase mutant. The FeLV-
GFP wild type was the pEECC-FeLV replication competent construct (NIH AIDS 
Reagent Program) that has the ires-gfp gene inserted into the env gene, 
previously described (Greggs, Clouser et al. 2012). The YMDD RT mutant was 
constructed by site directed mutating the valine of the normal Y[V]DD motif to a 
methionine to resemble the Y[M]DD motif of HIV-1. To synthesize this construct, 
a segment of RT was subcloned, using restriction enzyme MfeI (New England 
Biolabs).  Primers: CCTCCTACAATATATGGATGACCTCTT (forward) 
CCAGCAAGAGGTCATCCATATATTGT (reverse); were used to alter the Y[X]DD 
motif using site directed mutagenesis. The amplification conditions were 95 ºC for 
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1 min, followed by 18 cycles of 95ºC for 50 s,60 ºC for 50s, and 68 ºC for 6 min; 
and 68 ºC for 7 min. The RT segment was digest out of the pGEM-T vector with 
restriction enzymes MfeI and BspII. The RT segment was gel purified along with 
the original FeLV-GFP construct that was digested with the same restriction 
enzymes. These were gel purified using the wizard SV Gel and PCR Clean-Up 
Kit system (Promega). The FeLV-GFP plasmid was digested with Mfe I to 
linearize, and dephosphorylated with antarctic phosphatase (New England 
Biolabs). 
 The RT sequence and the FeLV-GFP backbone segment was ligated at 
4ºC in a 1:3 (plasmid backbone: DNA insert) molar ratio. The ligation product was 
transformed into DH5α (Escherichia coli) cells (Invitrogen) and plated onto Luria-
Bertani (LB) agar (Becton Dickinson) containing 50µg ampicillin ml-1. Individual 
colonies were selected and cultured in LB broth containing 50 µg ampicillin ml-1, 
which were purified using PureLink Quick Plasmid Miniprep kit (Invitrogen). 
Plasmid DNAs were sequenced to verify the creation of the desired mutant.  
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Table 3-1. Statistical analysis of the effects of decitabine, gemcitabine, and 
cyclopentenyl cytosine on the late phase of FeLV replication. The data 
represents the statistical analysis of target (CRFK) cells infected with FeLV 
produced in the presence or absence of drug. Data analyzed using two-tailed 
student t-test. 
 
 
Table 3-2. Statistical analysis of the effects of decitabine, gemcitabine, and 
cyclopentenyl cytosine on viral transfection efficiency. The data represents 
the statistical analysis of producer (293T) cell cotransfected with FeLV-GFP and 
VSV-G envelope in the presence or absence of drug. Data analyzed using two-
tailed student t-test. 
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Figure 3-1. Illustration of the chemical structure of cytosine analogs.  
Shown are the chemical structures of deoxycytidine and the cytosine analogs 
decitabine, gemcitabine, and cyclopentenyl cytosine (CPEC), as well as 
azidothymidine (AZT) and the cytosine analog lamivudine (3TC).  Figures were 
drawn using ChemBioDraw Ultra 13.0 software. 
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Figure 3-2. FeLV-GFP vector and model system for monitoring virus 
infectivity. (a) The FeLV vector, FeLV-GFP, shown with the gfp gene inserted in 
env gene. (b) Single-replication-cycle assay performed by infecting CRFK target 
cells. Infectious viral particles were created by the cotransfection of the FeLV-
GFP vector with the VSV-G envelope into 293T cells. Viral particles were 
harvested and used to infect CRFK target cells. Viral infectivity was monitored by 
flow cytometry. 
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Figure 3-3. Time-of-addition assay identifies reverse transcription as the 
antiviral target of decitabine, gemcitabine, and cyclopentenyl cytosine 
(CPEC). CRFK cell were infected with FeLV-GFP pseudotyped with VSV-G 
envelope. Cells were treated with the indicated drug for the indicated times post-
infection. Infectivity was measured by flow cytometry. Loss of infectivity was 
determined by a trending increase in GFP expression, which correlates to loss of 
drug activity (rebound in infection). 
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A) 
 
 
B) 
 
Figure 3-4. Antiviral activity of cyclopentenyl cytosine. MAGI cells pretreated 
for 24 h with the indicated concentrations of cyclopentenyl cytosine (CPEC), after 
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which they were infected with the pseudotyped (A) FeLV-GFP or (B) HIV-GFP 
viral stock. Flow cytometry was used to monitor infectivity. Data was normalized 
to the no drug control. IC50 values were calculated using GraphPad Prism. Data 
represents the mean with ± the standard error mean of 3 independent replicates.  
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Figure 3-5. Cytotoxic effects of cyclopentenyl cytosine in MAGI and CRFK 
cell lines. A) MAGI and B) CRFK cells were exposed to the indicated 
concentration of CPEC for 72 h. After which, they were tested for cell viability 
using the Promega CellTiter-Glo kit by adding a luciferase based substrate that 
emits light at 570 nm in the presence of ATP. Data was normalized to the no 
drug control. Data represents the mean with ± the standard error mean of 3 
independent replicates. 
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Figure 3-6. The potentiating effects of cyclopentenyl cytosine in 
combination with other cytosine analogs. MAGI cells were pretreated for 24 h 
with cyclopentenyl cytosine (CPEC) and the treated with AZT, with A) HIV-1 or B) 
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FeLV; decitabine with C) HIV or D) FeLV; or gemcitabine with E) HIV-1 or F) 
FeLV; 2 h prior to viral infection, at the concentrations indicated. Flow cytometry 
was used to monitor infectivity. Each treatment was normalized to no drug. Data 
represents the mean with ± the standard error mean of 3 independent replicates. 
Data was analyzed using a one-way ANOVA with a Tukey post test.  *** p ≤ 
0.001. 
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Figure 3-7. Decitabine, gemcitabine, and cyclopentenyl cytosine effects on 
the dNTP pools of MAGI and CRFK cell lines. MAGI or CRFK cells were 
treated with the indicated concentrations of AZT, decitabine, gemcitabine, or 
cyclopentenyl cytosine (CPEC). Twenty-four hours post-treatment, 3 x 106 cells 
were used for dNTP extraction in the MAGI cell line and 5 x 106 cells were used 
for dNTP extraction in the CRFK cell line. Liquid chromatography-tandem mass 
spectrometry (LCMS-MS) was used to monitor concentration of dATP A) MAGI, 
B) CRFK; dCTP C) MAGI, D) CRFK; dTTP E) MAGI F) CRFK; and dGTP G) 
MAGI H) CRFK. The LCMS-MS readings were normalized to an internal 
standard. Data was normalized to no drug (DMSO control). Data represents the 
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mean with ± the standard error mean of 3 independent replicates. Data was 
analyzed using a one-way ANOVA with a Tukey post test. * p ≤ 0.05, *** p ≤ 
0.001. 
 
A) 
 
B) 
  81 
 
Figure 3-8. Mutation frequency and spectra of FeLV in the presence of 
decitabine, gemcitabine, and cyclopentenyl cytosine. CRFK cells were 
pretreated with either decitabine 5 µM, gemcitabine 100 nM, or cyclopentenyl 
cytosine (CPEC) 1 µM for 2 h prior to infection. After 48 h post infection, the 
genomic DNA was extracted from the cells and the proviral DNA, as indicated in 
the Materials and Methods, was PCR amplified. The sequenced using Illumina 
DNA sequencing. A) The mutation frequency was calculated by the number of 
mutation per base sequenced. Data represents the mean with ± the 95 % 
confidence interval of 3 independent replicates. Data was analyzed using a one-
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way ANOVA with a Tukey post test. B) The FeLV mutation spectra was 
calculated by dividing the number of mutations for each mutation type by the total 
number of mutations observed for each drug treatment. For decitabine: A to T = 
285/3294,  G to C = 844/3294, C to T = 324/3294, G to A = 587/3294, all other 
mutation types = 1254/3294. For gemcitabine, A to T = 256/2204, G to C = 
415/2204, C to T = 308/2204, G to A = 513/2204, all other mutation types = 
712/2204. For cyclopentenyl cytosine, A to G = 297/2456, G to C = 356/2456, C 
to T = 287/2456, G to A = 601/2456, all other mutation types = 915/2456. For no 
drug (DMSO), A to G = 370/2242, G to C = 379/2242, C to T = 334/2242, G to A 
= 448/2242, all other mutations = 711/2242.  The calculated values were 
normalized and then multiplied by 100 to determine the percentage of the total. 
Data was analyzed using a one-way ANOVA with a Tukey post test.   
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Figure 3-9. Analysis of the effects of decitabine, gemcitabine, and 
cyclopentenyl cytosine on the late phase of FeLV replication. CRFK cells 
were infected with FeLV produced in the presence of drug. The post-integration 
antiviral effects of these drugs were evaluated by measuring changes in 
infectivity of drug treatments in comparison to no drug. Infectivity was monitored 
by flow cytometry.  Data represents the mean with ± the 95 % confidence interval 
of 5 or 9 independent replicates.  
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Figure 3-10. Analysis of the effects of decitabine, gemcitabine, and 
cyclopentenyl cytosine on viral transfection efficiency. 293T cells were 
cotransfected  with FeLV-GFP and VSV-G envelope in the presence or absence 
of drug, as illustrated. The virus was harvested 48 h post transfection and 
immediately used to infect target cells. The producer (293T) cells were collected 
and analyzed for post-integration effects of these compounds by using flow 
cytometry to monitor changes in GFP expression. Data represents the mean with 
± the 95 % confidence interval of 5 or 9 independent replicates.  
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G) 
 
 
Figure 3-11. The effects of a YVDD to YMDD reverse transcriptase 
phenotype on the susceptibility to cytosine analogs decitabine, 
gemcitabine, and cyclopentenyl cytosine. CRFK cells were infected with virus 
after a pretreated for 2 h with 3TC A). wild-type FeLV or B) YMDD mutant; 
decitabine C) wild-type FeLV or D) YMDD mutant;  gemcitabine E) wild-type 
FeLV or F) YMDD mutant; or cyclopentenyl cytosine (CPEC) G) YMDD-mutant. 
Flow cytometry was used to monitor infectivity 48 h post infection. Data 
normalized to no drug. IC50 values were calculated using GraphPad Prism. Data 
represents the mean with ± the standard error mean of 3 or 4 independent 
replicates. 
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Figure 3-12. Cytotoxic effects of 3TC in the CRFK cell line. CRFK cells were 
exposed to the indicated concentration of cyclopentenyl cytosine (CPEC) for 72 
h. Cells were then tested for cell viability using the Promega CellTiter-Glo kit by 
adding a luciferase based substrate that emits light at 570 nm in the presence of 
ATP. Data was normalized to no drug (see Materials and Methods). Data 
represents the mean with ± the standard error mean of 3 independent replicates. 
  90 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter IV 
 
Dissertation Summary and Final Discussion 
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Study summary 
 
 The content of this dissertation was inspired by the need for antiretrovirals 
for the treatment the feline leukemia virus (FeLV). FeLV is the most common 
cause of cancerous disease and immunodeficiencies in cats world wide. The 
need for new antiretrovirals for treatment also presented the opportunity to 
exploit FeLV as a model for understanding the breadth of the antiviral spectrum 
of activity for these cancer related compounds; decitabine, gemcitabine, and 
cyclopentenyl cytosine (CPEC), while understanding the mechanism by which 
they can elicit their antiviral activity. This dissertation outlines that decitabine, 
gemcitabine, and CPEC possess antiviral activity against FeLV in the nanomolar 
range. Unlike what was seen for HIV-1, my studies suggest that these drugs may 
not enhance FeLV mutagenesis.  Further research is needed to confirm this 
observation and to investigate other plausible mechanisms of action (e.g., 
inhibition of viral DNA synthesis). 
. 
Evaluation of chain-termination activity 
 In order to evaluate if decitabine, gemcitabine, or CPEC are acting by 
inhibiting RT production, it is important to utilize quantitative PCR (qPCR) to 
monitor changes in late RT products when the virus is exposed to drug. If the 
drug elicits chain-terminating activity, as you would see with AZT or tenofovir, 
one would expect a decrease in late RT products detectable by qPCR. Because 
our data thus far suggests that these cytosine analogs have activity during the 
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reverse transcription phase of the retroviral life cycle, this is a likely candidate for 
the antiviral mechanism that should be further investigated.  
 
Confirmation of viral DNA sequencing 
 To address the issue with elevated background that occurs with Illumina 
DNA sequencing, Sanger DNA sequencing could be done using the fluorescence 
protein gene, gfp. This would allow independent evaluation the mutagenic 
potential using a different DNA sequencing methodology. In the case of 
decitabine, it is believed that in HIV-1 its mutation activity is based on drug 
incorporation into the viral genome. This could be directly investigated by utilizing 
radio-labeling the compounds to visualize drug incorporation. This in vitro assay 
would involve negating cellular dependant mechanisms like drug phosphorylation 
and transport, allowing for addressing the simple question of whether these 
drugs could be substrates for FeLV reverse transcriptase. 
 
Evaluation of the potential for clinical translation 
 Ultimately, clinical studies should be done to address the pharmacokinetic, 
pharmacodynamics, and cytotoxicity of decitabine, gemcitabine, and CPEC as 
antiretrovirals for FeLV. Though my study investigated cellular toxicity in a feline 
cell line, in order to get an accurate evaluation of toxicity, it is necessary to 
analyze this in vivo. This would address issues of drug activation, accumulation 
in tissues, targeted organ or cell type toxicity, etc. This would also assess the 
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clinical relevance of these compounds as antiretrovirals against FeLV. Since 
gemcitabine is currently approved as a cancer therapeutic in cats, there exist 
some information for the pharmacokinetics, and pharmacodynamics of this drug 
in felines. The use of gemcitabine for anti-FeLV therapy would involve 
significantly lower dosing, as indicated by this dissertation.  Other drugs would 
need to have acceptable therapeutic indices.  Currently, these drugs are given 
intravenously. A more compliant treatment regimen would be per os, so attempts 
have to be made to make these compounds orally available. Studies have been 
done to testing orally available derivative of decitabine and gemcitabine 
described by Clouser et al (2013); and so an extension of that study for FeLV 
infection would be important. Clinically, some cats that become infected can clear 
the infection. This mechanism for viral clearance is not completely understood. In 
practice, if safe antiretroviral can be given during early infection, it is possible to 
aid the newly infected cats with overcoming viral infection. The animal study 
should extend into exploring the role of antiretrovirals in latent and rebound 
infections in order to increase the probability of natural clearance and immunity in 
FeLV infected cats. 
 The use of anti-FeLV drugs would have the greatest clinical impact during 
the early stages of viral infection and prior to the onset of clinical pathology. A 
limitation of using nucleoside analogs is an active viral infection.  Latent viral 
infections in the bone marrow would not be expected to be susceptible.  
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IIlUMINA® NEXT-GENERATION SEQUENCING BARCODE LIST 
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Table I-1. List of the Illumina® barcodes and primers used in next-
generation sequencing.  
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APPENDIX II 
Liquid Chromatography-Tandem Mass Spectrometry Parameters 
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Analyte ESI 
mode Q1 Q3 DP
a
 EPb CEc CXPd 
dCTP – 466.1 159.0 –55 10 –32 –14 
dTTP – 481.1 159.0 –52 10 –32 –15 
dATP – 490.1 159.0 –35 10 –34 –14 
IS – 591.8 511.8 –47 10 –36 –22 
dGTP + 581.0 152.1 39 10 34 17 
 
 
Table II-1. LCMS-MS parameters for detection of deoxynucleotides and 
internal standard. aDeclustering potential; bEntrance potential; cCollision energy; 
dCollision cell exit potential. 
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Figure II-1. Illustration of the dNTP fragmentation pattern.  dCTP, dTTP, and 
dATP all have the same fragmentation pattern.  dGTP has a unique 
fragmentation pattern to distinguish it from ATP.   
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A) 
 
 
B) 
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Figure II-2. Example of LCMS-MS chromatogram with DMSO (no drug) 
control.  Cells were plated on a 10 cm dish and treated with DMSO for 4 hours.  
Treated cells are collected, counted, and methanol treated to extract dNTPs.  
The methanol treatment was spiked with 5'-Iodo-2'dCTP (internal standard, IS) 
and incubated overnight.  dNTP were collected from the supernatant and LCMS-
MS was conducted to calculate peak areas for A) dATP, dCTP, dTTP, and B) 
dGTP (see Materials and Methods for details). 
 
  
